CClinicalTrials.gg
CompletedNCT05098158COMFORTUpdated Oct 6, 2025Results posted

Community-Engaged Options to Facilitate Opioid Reduction

An interventional study of Non-pharmacological pain treatment in Chronic Pain, sponsored by Washington State University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Washington State University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study investigates how adults prescribed opioids for chronic noncancer pain respond to invitations to try non-opioid options of massage therapy, yoga therapy, chiropractic and physical therapies. Options will be available via telehealth consultation visits using a computer or smartphone with internet connection. The investigators will measure effects on pain, pain-related symptoms, and opioid use over time using a single-group design.

Read the detailed description

Participants will be recruited from local primary care practices and asked to complete a baseline survey. They will then meet with a registered nurse via teleconference for a complete pain assessment. At the end of the session, participants will be asked to choose two of four available modalities for telehealth consultation. Participants will be scheduled for six telehealth sessions, once per week x six weeks with three consultations per each chosen therapy. Measurements of pain, mood, sleep, medicine use will be captured at baseline, three weeks and six weeks and examined for changes over time.

02

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • chronic pain
  • opioid
  • complementary
03

In context

Chronic Pain

2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.

This study's enrollment of 21 is below the median of 60 across 2,161 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Washington State University is the lead sponsor of 82 studies on the registry; 16 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • enrollment in treatment at the CHAS Perry St or partnering clinic;
  • age greater than 18 years;
  • ability to read, speak, and write English;
  • diagnosed with a chronic, non-cancer-based painful medical condition;
  • ability to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • pregnancy;
  • diagnosis of a cancer-based painful medical condition;
  • any other medical or psychiatric condition that the PI or Co-PI physician of record determine might compromise safe study participation (including but not limited to active psychosis, history of frequent psychiatric hospitalizations, severe anxiety with claustrophobia, aggression)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Single arm pain treatment

    Arm includes usual pain care plus the chosen two telehealth interventions x 6 weeks

    Other: Non-pharmacological pain treatment

Interventions

  • OtherNon-pharmacological pain treatment

    Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.

06

What researchers measure

Primary outcomes

  1. Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Rating

    Full scale name is PROMIS (Patient-Reported Outcome Measurement Information System) Pain Intensity Scale version 3a that measures the construct pain intensity or severity in three items for how much it hurts on average, at its worst and at its least in the past 7 days. Scale ranges from minimum "no pain" =1 to maximum "very severe" =5 pain with a possible sum of 3-15. A total sum of the 3 items is converted into a T-score where 50 is equivalent to the U.S. general population average and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a worse outcome (range 40-70 after T-score conversion).

    Time frame: 6 weeks

  2. PROMIS Pain Interference Rating

    Scale name is PROMIS (Patient-Reported Outcome Measurement Information System) Pain Interference Scale that measures the construct pain interference in 8 items for how much pain interferes with a variety of activities in the past 7 days. Scale ranges from minimum "not at all" =1 to maximum "very much" =5 pain with a possible sum of 8-40. A total sum of the 8 items is converted into a T-score where 50 is equivalent to the U.S. general population average and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a worse outcome.

    Time frame: 6 weeks

Secondary outcomes

  1. Depressive Symptoms Using Patient Health Questionnaire (PHQ-8)

    Patient Health Questionnaire (PHQ-8) 8-item scale with score range 0-24 (higher score is worsened depressive symptoms)

    Time frame: 6 weeks

  2. PROMIS Self-efficacy for Managing Symptoms Short Form 4a

    Self-efficacy self-report (range 4-20 with higher score better symptom management self-efficacy). Scores converted into T scores with 50 as the average for US adults and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a better outcome (range 40-70 after T-score conversion).

    Time frame: 6 weeks

  3. PROMIS Self-efficacy for Managing Emotions Short Form 4a

    Self-efficacy self-report (range 4-20 ). Converted to T score where 50 equals the US adults average and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a better outcome for self-efficacy for managing emotions (range 40-70 after T-score conversion).

    Time frame: 6 weeks

  4. Anxiety Using Generalized Anxiety Disorder (GAD-7)

    7-item scale with score range 0-21 (higher score is worsened anxiety)

    Time frame: 6 weeks

  5. Interpersonal Needs Questionnaire

    9-item scale asking how one feels about others score range 0-28 (lower score indicates more unmet interpersonal needs)

    Time frame: 6 weeks

  6. Current Opioid Misuse Measure

    17-item scale to ask about use of opioids (range 0-64 with higher scores indicating more misuse)

    Time frame: 6 weeks

  7. Spiritual Well-being Index

    4-items to ask about spiritual well-being (range 4-20 with higher scores indicating more spiritual well-being)

    Time frame: 6 weeks

Other outcomes

  1. Percentage of Attendance in Scheduled Telehealth Sessions

    Percentage of scheduled telehealth sessions attended by participants (calculated as total number attended/total number scheduled)

    Time frame: 6 weeks

  2. IBM Computer Usability and Satisfaction Questionnaires

    The IBM Computer Usability and Satisfaction Questionnaires was adapted to measure tele-visit program usability and satisfaction with a 4-item survey to gauge participant satisfaction with the intervention using 1-7 Likert scale. A total mean satisfaction rating was generated from the combined mean 4 satisfaction items (possible mean range 1-7 where higher score means higher satisfaction) on a Likert-style scale: The Likert-style scale for each item was: 1: Strongly disagree- 7: Strongly agree where higher numbers indicate greater satisfaction.

    Time frame: 6 weeks

07

Results

Posted Oct 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneSingle Arm Pain Treatment
Started16
Yoga intervention11
Physical therapy intervention9
Massage intevention8
Chiropractic intervention4
Completed15
Not completed1

Outcome measures

PrimaryPatient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Rating

Full scale name is PROMIS (Patient-Reported Outcome Measurement Information System) Pain Intensity Scale version 3a that measures the construct pain intensity or severity in three items for how much it hurts on average, at its worst and at its least in the past 7 days. Scale ranges from minimum "no pain" =1 to maximum "very severe" =5 pain with a possible sum of 3-15. A total sum of the 3 items is converted into a T-score where 50 is equivalent to the U.S. general population average and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a worse outcome (range 40-70 after T-score conversion).

Time frame:
6 weeks
Reported as:
Mean · score on a scale
Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Rating
score on a scaleSingle Arm Pain Treatment
Pre68.3 ± 6.3
Post64.4 ± 6.0
Statistical analysis
  • Single Arm Pain Treatment · t-test, 2 sided · p = <0.001 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (final values): 3.9
PrimaryPROMIS Pain Interference Rating

Scale name is PROMIS (Patient-Reported Outcome Measurement Information System) Pain Interference Scale that measures the construct pain interference in 8 items for how much pain interferes with a variety of activities in the past 7 days. Scale ranges from minimum "not at all" =1 to maximum "very much" =5 pain with a possible sum of 8-40. A total sum of the 8 items is converted into a T-score where 50 is equivalent to the U.S. general population average and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a worse outcome.

Time frame:
6 weeks
Reported as:
Mean · units on a scale
PROMIS Pain Interference Rating
units on a scaleSingle Arm Pain Treatment
Pre69.9 ± 5.5
Post64.3 ± 8.3
Statistical analysis
  • Single Arm Pain Treatment · t-test, 2 sided · p = 0.003 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (final values): 5.6
SecondaryDepressive Symptoms Using Patient Health Questionnaire (PHQ-8)

Patient Health Questionnaire (PHQ-8) 8-item scale with score range 0-24 (higher score is worsened depressive symptoms)

Time frame:
6 weeks
Reported as:
Mean · score on a scale
Depressive Symptoms Using Patient Health Questionnaire (PHQ-8)
score on a scaleSingle Arm Pain Treatment
Pre10.7 ± 5.9
Post7.6 ± 5.0
Statistical analysis
  • Single Arm Pain Treatment · t-test, 2 sided · p = 0.011 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (final values): 3.1
SecondaryPROMIS Self-efficacy for Managing Symptoms Short Form 4a

Self-efficacy self-report (range 4-20 with higher score better symptom management self-efficacy). Scores converted into T scores with 50 as the average for US adults and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a better outcome (range 40-70 after T-score conversion).

Time frame:
6 weeks
Reported as:
Mean · units on a scale
PROMIS Self-efficacy for Managing Symptoms Short Form 4a
units on a scaleSingle Arm Pain Treatment
Pre39.4 ± 5.2
Post41.2 ± 5.3
Statistical analysis
  • Single Arm Pain Treatment · t-test, 2 sided · p = 0.168 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (final values): 1.9
SecondaryPROMIS Self-efficacy for Managing Emotions Short Form 4a

Self-efficacy self-report (range 4-20 ). Converted to T score where 50 equals the US adults average and + /- 10 points is equivalent to the standard deviation. Higher values are considered to be a better outcome for self-efficacy for managing emotions (range 40-70 after T-score conversion).

Time frame:
6 weeks
Reported as:
Mean · units on a scale
PROMIS Self-efficacy for Managing Emotions Short Form 4a
units on a scaleSingle Arm Pain Treatment
Pre43.4 ± 6.3
Post44.4 ± 5.1
Statistical analysis
  • Single Arm Pain Treatment · t-test, 2 sided · p = 0.456 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (final values): 1.1
SecondaryAnxiety Using Generalized Anxiety Disorder (GAD-7)

7-item scale with score range 0-21 (higher score is worsened anxiety)

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Anxiety Using Generalized Anxiety Disorder (GAD-7)
units on a scaleSingle Arm
Pre5.9 ± 4.7
Post5.2 ± 5.2
Statistical analysis
  • Single Arm · t-test, 2 sided · p = 0.517 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (final values): .8
SecondaryInterpersonal Needs Questionnaire

9-item scale asking how one feels about others score range 0-28 (lower score indicates more unmet interpersonal needs)

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Interpersonal Needs Questionnaire
units on a scaleSingle Arm
Pre27.7 ± 14.4
Post24.5 ± 13.5
Statistical analysis
  • Single Arm · t-test, 2 sided · p = 0.012 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (net): 3.2
SecondaryCurrent Opioid Misuse Measure

17-item scale to ask about use of opioids (range 0-64 with higher scores indicating more misuse)

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Current Opioid Misuse Measure
units on a scaleSingle Arm
Pre7.1 ± 4.9
Post6.8 ± 4.4
Statistical analysis
  • Single Arm · t-test, 2 sided · p = 0.811 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (net): 0.3
SecondarySpiritual Well-being Index

4-items to ask about spiritual well-being (range 4-20 with higher scores indicating more spiritual well-being)

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Spiritual Well-being Index
units on a scaleSingle Arm
Pre15 ± 4.1
Post15.1 ± 3.5
Statistical analysis
  • Single Arm · t-test, 2 sided · p = 0.941 (Actual p value results above; Not adjusted due to pilot study aim to generate effect size comparing pre and posttest data) · Mean difference (final values): 0.1
Other pre-specifiedPercentage of Attendance in Scheduled Telehealth Sessions

Percentage of scheduled telehealth sessions attended by participants (calculated as total number attended/total number scheduled)

Time frame:
6 weeks
Reported as:
Number · percentage of sessions attended
Percentage of Attendance in Scheduled Telehealth Sessions
percentage of sessions attendedSingle Arm
Percentage of Attendance in Scheduled Telehealth Sessions95.8
Statistical analysis
  • Single Arm · Percentage: 95.8
Other pre-specifiedIBM Computer Usability and Satisfaction Questionnaires

The IBM Computer Usability and Satisfaction Questionnaires was adapted to measure tele-visit program usability and satisfaction with a 4-item survey to gauge participant satisfaction with the intervention using 1-7 Likert scale. A total mean satisfaction rating was generated from the combined mean 4 satisfaction items (possible mean range 1-7 where higher score means higher satisfaction) on a Likert-style scale: The Likert-style scale for each item was: 1: Strongly disagree- 7: Strongly agree where higher numbers indicate greater satisfaction.

Time frame:
6 weeks
Reported as:
Mean · mean of summed scores on a scale
IBM Computer Usability and Satisfaction Questionnaires
mean of summed scores on a scaleSingle Arm
IBM Computer Usability and Satisfaction Questionnaires6.59 ± 0.62

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm Pain Treatment0/16 (0%)0/16 (0%)1/16 (6.3%)
Most frequent other events
Most frequent other events
EventSingle Arm Pain Treatment
MildEar and labyrinth disorders1/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Single Arm Pain Treatment
<=18 years0
Between 18 and 65 years12
>=65 years4
Age, Continuous
Age, Continuous(years)Single Arm Pain Treatment
Mean60.4 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm Pain Treatment
Female12
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm Pain Treatment
Hispanic or Latino1
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm Pain Treatment
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Single Arm Pain Treatment
United States16
PROMIS Pain Intensity Scale
PROMIS Pain Intensity Scale(units on a scale)Single Arm Pain Treatment
Mean68.6 ± 6.5
08

Study locations

2 sites
  • Community Health Association of Spokane
    Spokane, Washington 99201, United States
  • Washington State University College of Nursing
    Spokane, Washington 99201, United States
09

References and documents

Study documents

  • Protocol, analysis plan and consent form · Jan 15, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05098158
Lead sponsor
Washington State University
Collaborators
Spokane Regional Health District, University of Washington Institute for Translational Health Science (KL2), Rayce Rudeen Foundation
Responsible party
Marian Wilson (Associate Professor, Washington State University) — Principal investigator
First posted
Oct 28, 2021
Start date
Jul 10, 2020
Primary completion
Jan 3, 2022
Completion
Jan 3, 2022
Results posted
Oct 6, 2025
Last update
Oct 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion